Enrolling Participants in Cutting-Edge Vaccine Trial for Pediatric Ependymomas Researchers at Children’s Hospital of Pittsburgh of UPMC are enrolling children with recurrent ependymoma on a research study using a vaccine targeted against three proteins commonly found on the surface of ependymoma cells. Patients must be 12 months to 22 years of age at the time of study entry, must have a certain tissue type known as HLA-A2, found in 45% of the population, and must be willing to travel to Pittsburgh to receive the vaccines. Testing for HLA-A2 status is done as part of the research study through a blood test drawn locally, with a 24- to 48-hour turn-around time. Vaccines are administered every three weeks x 8 and then every six weeks x 12. To find out more about the study “Immunotherapy for Recurrent Ependymomas in Children,” contact Mia Salimbene, clinical research coordinator, at [email protected] or 412-692-6185. More information is available on clinicaltrials.gov.
Posted on: Mon, 22 Dec 2014 22:40:00 +0000
Trending Topics
Recently Viewed Topics
© 2015